Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Song, Jingjiao ^a   Zhou, Yun ^b   Li, Sheng ^b   Wang, Baoju ^b   Zheng, Xin ^b   Wu, Jun ^b   Gibbert, Kathrin ^c   Dittmer, Ulf ^c   Lu, Mengji ^c   Yang, Dongliang ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; VIRUS DNA; VIRUS VECTOR; ANTIVIRUS AGENT; CYTOKINE; INTERFERON REGULATORY FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HYDRODYNAMIC INJECTION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INJECTION; ISG15 GENE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OAS GENE; PKR GENE; PROTEIN EXPRESSION; VIRAL GENE THERAPY; VIRUS GENE; VIRUS GENOME; VIRUS ISOLATION; VIRUS REPLICATION; ADMINISTRATION AND DOSAGE; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER; METABOLISM; MICROBIAL SENSITIVITY TEST; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENETIC VECTORS; GENOTYPE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; LIVER; MALE; MICE; MICROBIAL SENSITIVITY TESTS; T-LYMPHOCYTE SUBSETS; VIRAL LOAD;

EID: 84897552993     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090977     Document Type: Article

References (56)

1. Lavanchy D (2005) Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 34: S1-3.
2. McMahon BJ (2005) Epidemiology and natural history of hepatitis B. Semin Liver Dis 25: S3-8.
3. Kao JH (2011) Molecular epidemiology of hepatitis B. Korean J Intern Med 26: 255-261.
4. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, et al. (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348: 808-816. (Pubitemid 36245757)
5. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, et al. (2010) Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 52: 176-182.
6. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, et al. (2011) Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 53: 62-72.
7. Sadler AJ, Williams BR (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8: 559-568. (Pubitemid 351913674)
8. Chevaliez S, Pawlotsky JM (2009) Interferons and their use in persistent viral infections. Handb Exp Pharmacol 189: 203-241.
9. Hoofnagle JH, Di Bisceglie AM (1997) The treatment of chronic viral hepatitis. N Engl J Med 336: 347-356.
10. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, et al. (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119: 312-323. (Pubitemid 23319890)
11. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, et al. (1996) Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334: 1422-1427. (Pubitemid 26157437)
12. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, et al. (2006) Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101: 297-303. (Pubitemid 43381671)
13. Ferir G, Kaptein S, Neyts J, De Clercq E (2008) Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev Med Virol 18: 19-34. (Pubitemid 351155900)
14. Kao JH (2007) Appropriate use of interferon for treatment of chronic hepatitis B. Hepatol Res 37: S47-54.
15. Wang Y, Wei L, Jiang D, Cong X, Fei R, et al. (2007) In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation. Antiviral Res 75: 139-145. (Pubitemid 46669709)
16. Boglione L, D'Avolio A, Cariti G, Milia MG, Simiele M, et al. (2013) Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J Viral Hepat 20: e11-19.
17. Westland C, Delaney W, Yang H (2003). Hepatitis B virus genotypes and virological response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 125: 107-116. (Pubitemid 36799112)
18. Lurie Y, Manns MP, Gish RG (2005) The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naive, HbeAg(+) and HbeAg (-) patients with chronic hepatitis B. J Hepatol 42: S84.
19. Wiegand J, Hasenclever D, Tillmann HL (2008) Should treatment of hepatitis B depend on hepatitis B virus genotype A hypothesis generated from an explorative analysis of published evidence. Antivir The 13: 211-220. (Pubitemid 351535372)
20. Moucari R, Martinot-Peignoux M, Mackiewicz V, Boyer N, Ripault MP, et al. (2009) Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a. Antivir Ther 14: 1183-1188.
21. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS (2000). Hepatitis B genotypes and the response to interferon therapy. J Hepatol 33: 998-1002.
22. Tseng TC, Kao JH (2008) HBV genotype and clinical outcome of chronic hepatitis B facts and puzzles. Gastroenterology 134: 1272-1273.
23. Foster GR, Finter NB (1998) Are all type I human IFNs equivalent? Rev J Viral Hepatitis 5: 143-152. (Pubitemid 28374722)
24. Kelley KA, Pitha PM (1985) Characterization of a mouse IFN gene locus II. Differential expression of alpha-interferon genes. Nucl Acids Res 13: 825-839.
25. Zwarthoff EC, Mooren ATA, Trapman J (1985) Organisation, structure and expression of murine interferon alpha genes. Nucl Acids Res 13: 791-804.
26. Samuel CE (2001) Antiviral actions of interferons. Clin Microbiol Rev 14: 778-809, table of contents.
27. Kalvakolanu DV (2003) Alternate interferon signaling pathways. Pharmacol Ther 100: 1-29.
28. Thomas H, Foster G, Platis D (2003) Mechanisms of action of interferon and nucleoside analogues. J Hepatol 39: S93-98. (Pubitemid 37222654)
29. Wieland SF, Vega RG, Müller R, Evans CF, Hilbush B, et al. (2003) Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 77: 1227-1236. (Pubitemid 36055546)
30. Isogawa M, Robek MD, Furuichi Y, Chisari FV (2005) Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 79: 7269-7272. (Pubitemid 40677357)
31. Wu J, Lu M, Meng Z, Trippler M, Broering R, et al. (2007) Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 46: 1769-1778.
32. Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV (2005) Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci USA 102: 9913-9917. (Pubitemid 40993667)
33. Tian Y, Chen WL, Ou JH (2011) Effects of interferon-α/β on HBV replication determined by viral load. PLoS Pathog 7: e1002159.
34. Zhang Y, Wu Y, Ye S, Wang T, Zhao R, et al. (2013) The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo. Virus Res 171: 65-70.
35. Marié I, Durbin JE, Levy DE (1998) Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J 17: 6660-6669. (Pubitemid 28521799)
36. Lei YC, Hao YH, Zhang ZM, Tian YJ, Wang BJ, et al. (2006) Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo. World J Gastroenterol 12: 4492-4497.
37. Huang LR, Wu HL, Chen PJ, Chen DS (2006) An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA. 103: 17862-17867.
38. Cull VS, Bartlett EJ, James CM (2002) Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis. Immunology 106: 428-437. (Pubitemid 34748138)
39. Lu M, Isogawa M, Xu Y, Hilken G (2005) Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks. J Virol 79: 6368-6376. (Pubitemid 40617240)
40. Mendy ME, Kaye S, van der Sande M, Rayco-Solon P, Waight PA, et al. (2006) Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in The Gambia. Virology 3: 23.
41. Meng Z, Xu Y, Wu J, Tian Y, Kemper T, et al. (2008) Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA. J Virol Methods 150: 27-33.
42. von Freyend MJ, Untergasser A, Arzberger S, Oberwinkler H, Drebber U, et al. (2011) Sequential control of hepatitis B virus in a mouse model of acute, self-resolving hepatitis B. J Viral Hepat 18: 216-226.
43. Zhang X, Zhang E, Ma Z, Pei R, Jiang M, et al. (2011) Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology 53: 1476-1485.
44. Wieland SF, Guidotti LG, Chisari FV (2000) Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 74: 4165-4173. (Pubitemid 30214422)
45. Wieland S, Thimme R, Purcell RH, Chisari FV (2004) Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 101: 2129-2134.
46. Chen J, Wu M, Zhang X, Zhang W, Zhang Z, et al. (2013) Hepatitis B virus polymerase impairs interferon-α induced STA T activation through inhibition of importin-α5 and protein kinase C-δ. Hepatology 57: 470-482.
47. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J (2002) Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 123: 1848-56.
48. Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, et al. (2000) Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 31: 716-725. (Pubitemid 30118641)
49. Hou J, Schilling R, Janssen HL, Hansen BE, Heijtink R, et al. (2007) Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol 79: 1055-1063. (Pubitemid 47015403)
50. Yu X, Mertz JE (1996) Promoters for synthesis of the pre-C and pregenomic mRNAs of human hepatitis B virus are genetically distinct and differentially regulated. J Virol 70: 8719-8726. (Pubitemid 26378454)
51. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH (1996) Effects of a naturally occurred mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 70: 5845-5851. (Pubitemid 26266795)
52. Li J, Buckwold VE, Hon MW, Ou JH (1999) Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J Virol 73: 1239-1244. (Pubitemid 29036777)
53. Guidotti LG, Matzke B, Pasquinelli C, Shoenberger JM, Rogler CE, et al. (1996) The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J Virol 70: 7056-7061. (Pubitemid 26307420)
54. Scaglioni PP, Melegari M, Wands JR (1997) Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J Virol 71: 345-353. (Pubitemid 26412298)
55. Chen H-S, Kaneko S, Girones R, Anderson RW, Hornbuckle WE, et al. (1993) The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol 67: 1218-1226. (Pubitemid 23067624)
56. Zoulim F, Saputelli J, Seeger C (1994) Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 68: 2026-2030. (Pubitemid 24065779)